ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

House Passes Cancer Bill With Mandates for NCI

September 28, 2012

NTP Board Okays concept for New In Vitro study Using Oncogenes

May 10, 1985

FDA Approves Erbitux for Head & Neck Cancer.

March 3, 2006

In Brief: NCI To Go Along With NCAB on Keeping Clinical Education Program Alive; Cal Baldwin Retires

February 28, 1986

In Brief: CT Scanning Of The Brain Subject Of Consensus Development Conference; CCI Plans Congress Events

July 10, 1981

ACS President Huerta Disagrees With Staff On Cell Phone Danger.

August 1, 2008